Literature DB >> 1324440

Sigma receptors in schizophrenic cerebral cortices.

H Shibuya1, H Mori, M Toru.   

Abstract

Antipsychotics represent high affinity for sigma receptors and sigma-like drugs often have the psychotomimetic properties. Besides, the receptors are unevenly distributed in human brain. These findings suggest that sigma receptors might be involved in the pathophysiology of schizophrenia. Sigma receptors in rat and human brain were measured with [3H]-1, 3, di-o-tolylguanidine (DTG) and non-specific binding of [3H]DTG was determined in the presence of 10(-5)M haloperidol. Monovalent and divalent cations strongly inhibited [3H]DTG binding. Glutamate, aspartate and glycine also decreased the binding to human cerebral membranes. With post-mortem brain samples from 12 schizophrenics and 10 controls, sigma receptors were measured in 17 areas of cerebral cortex. Sigma receptors binding showed the regional differences in the cortex, but no significant differences between schizophrenics and controls were observed except the superior parietal cortex where the binding significantly increased in the schizophrenic group. These results suggest that sigma receptors in cerebral cortices might not be directly concerned with the pathophysiological role in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324440     DOI: 10.1007/bf00966825

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  29 in total

1.  Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients.

Authors:  M Toru; S Watanabe; H Shibuya; T Nishikawa; K Noda; H Mitsushio; H Ichikawa; A Kurumaji; M Takashima; N Mataga
Journal:  Acta Psychiatr Scand       Date:  1988-08       Impact factor: 6.392

2.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

3.  Phencyclidine and sigma opiate receptors in brain: biochemical and autoradiographical differentiation.

Authors:  A L Gundlach; B L Largent; S H Snyder
Journal:  Eur J Pharmacol       Date:  1985-07-31       Impact factor: 4.432

4.  Different modulation of the binding to two phencyclidine (PCP) receptor subtypes: effects of N-methyl-D-aspartate agonists and antagonists.

Authors:  Y Itzhak
Journal:  Neurosci Lett       Date:  1989-10-09       Impact factor: 3.046

Review 5.  Phencyclidine and psychotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action.

Authors:  M S Sonders; J F Keana; E Weber
Journal:  Trends Neurosci       Date:  1988-01       Impact factor: 13.837

6.  Demonstration of [3H]cyclazocine binding to multiple opiate receptor sites.

Authors:  R S Zukin; S R Zukin
Journal:  Mol Pharmacol       Date:  1981-09       Impact factor: 4.436

7.  Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine.

Authors:  B L Largent; A L Gundlach; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1986-08       Impact factor: 4.030

8.  Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine.

Authors:  A L Gundlach; B L Largent; S H Snyder
Journal:  J Neurosci       Date:  1986-06       Impact factor: 6.167

9.  Stereoisomers of N-allylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats.

Authors:  K T Brady; R L Balster; E L May
Journal:  Science       Date:  1982-01-08       Impact factor: 47.728

10.  Pharmacological specificity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sites.

Authors:  Y Itzhak
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

View more
  10 in total

Review 1.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

Review 2.  Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry.

Authors:  G Debonnel
Journal:  J Psychiatry Neurosci       Date:  1993-07       Impact factor: 6.186

Review 3.  Reviewing the ketamine model for schizophrenia.

Authors:  Joel Frohlich; John D Van Horn
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

4.  Characterization of [3H]pentazocine binding sites in post-mortem human frontal cortex.

Authors:  J Kornhuber; K Schoppmeyer; C Bendig; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 5.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  The sigma-1 receptor: roles in neuronal plasticity and disease.

Authors:  Saïd Kourrich; Tsung-Ping Su; Michiko Fujimoto; Antonello Bonci
Journal:  Trends Neurosci       Date:  2012-10-23       Impact factor: 13.837

7.  Newer molecules in the treatment of schizophrenia: A clinical update.

Authors:  Abhishek Ghosh; Kaustav Chakraborty; Surendra Kumar Mattoo
Journal:  Indian J Pharmacol       Date:  2011-04       Impact factor: 1.200

8.  The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders.

Authors:  María Rodríguez-Muñoz; Elsa Cortés-Montero; Andrea Pozo-Rodrigálvarez; Pilar Sánchez-Blázquez; Javier Garzón-Niño
Journal:  Oncotarget       Date:  2015-11-03

Review 9.  Ketamine plus Alcohol: What We Know and What We Can Expect about This.

Authors:  Natalia Harumi Correa Kobayashi; Sarah Viana Farias; Diandra Araújo Luz; Kissila Márvia Machado-Ferraro; Brenda Costa da Conceição; Cinthia Cristina Menezes da Silveira; Luanna Melo Pereira Fernandes; Sabrina de Carvalho Cartágenes; Vânia Maria Moraes Ferreira; Enéas Andrade Fontes-Júnior; Cristiane do Socorro Ferraz Maia
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

10.  Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.

Authors:  María Rodríguez-Muñoz; Yara Onetti; Elsa Cortés-Montero; Javier Garzón; Pilar Sánchez-Blázquez
Journal:  Mol Brain       Date:  2018-09-17       Impact factor: 4.041

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.